RJFSA
TCRT icon

Raymond James Financial Services Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-97
Closed -$7.43K – 3346
2023
Q2 		$7.43K Hold
97
– – ﹤0.01% 3215
2023
Q1 		$9.18K Hold
97
– – ﹤0.01% 3229
2022
Q4 		$9.47K Sell
97
-38
-28% -$5.51K ﹤0.01% 3196
2022
Q3 		$35K Sell
135
-1
-0.7% -$290 ﹤0.01% 3122
2022
Q2 		$25K Buy
136
+44
+48% +$4.21K ﹤0.01% 3146
2022
Q1 		$9K Sell
92
-47
-34% -$6.03K ﹤0.01% 3297
2021
Q4 		$23K Sell
139
-24
-15% -$5.27K ﹤0.01% 3232
2021
Q3 		$44K Buy
163
+31
+23% +$9.48K ﹤0.01% 3196
2021
Q2 		$52K Sell
132
-30
-19% -$14K ﹤0.01% 3206
2021
Q1 		$87K Buy
162
+41
+34% +$25.5K ﹤0.01% 3056
2020
Q4 		$46K Sell
121
-2
-2% -$795 ﹤0.01% 2917
2020
Q3 		$46K Sell
123
-9
-7% -$3.98K ﹤0.01% 2772
2020
Q2 		$65K Hold
132
– – ﹤0.01% 2689
2020
Q1 		$49K Sell
132
-30
-19% -$15.5K ﹤0.01% 2316
2019
Q4 		$115K Buy
+162
New +$111K ﹤0.01% 2687
2019
Q3 		– Sell
-358
Closed -$313K – 2925
2019
Q2 		$313K Buy
358
+64
+22% +$44K ﹤0.01% 2243
2019
Q1 		$170K Sell
294
-19
-6% -$7.94K ﹤0.01% 2537
2018
Q4 		$88K Buy
+313
New +$124K ﹤0.01% 2414
2018
Q3 		– Sell
-941
Closed -$426K – 2889
2018
Q2 		$426K Sell
941
-78
-8% -$49.5K ﹤0.01% 1983
2018
Q1 		$599K Buy
1,019
+23
+2% +$14.3K ﹤0.01% 1610
2017
Q4 		$618K Buy
996
+76
+8% +$54.6K ﹤0.01% 1586
2017
Q3 		$847K Buy
920
+42
+5% +$37.3K 0.01% 1415
2017
Q2 		$819K Sell
878
-18
-2% -$17.6K 0.01% 1389
2017
Q1 		$852K Sell
896
-11
-1% -$10.2K 0.01% 1276
2016
Q4 		$728K Sell
907
-206
-19% -$186K 0.01% 1297
2016
Q3 		$940K Sell
1,113
-165
-13% -$133K 0.01% 1118
2016
Q2 		$1.05M Sell
1,278
-7
-0.5% -$7.62K 0.01% 1009
2016
Q1 		$1.43M Buy
1,285
+49
+4% +$50.1K 0.02% 757
2015
Q4 		$1.54M Buy
1,236
+471
+62% +$779K 0.02% 746
2015
Q3 		$1.03M Buy
+765
New +$1.26M 0.02% 761

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Raymond James Financial Services Advisors's TCRT Position: Q3 2023 in Review

Raymond James Financial Services Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2023, closing a stake of 97 shares — an estimated $7.43K sold.

Raymond James Financial Services Advisors first reported a position in TCRT in Q3 2015 and held it in 30 quarters. The position peaked at $1.54M in Q4 2015. 89 funds tracked by Wall St. Rank hold TCRT as of Q3 2023.

  • Raymond James Financial Services Advisors reported no remaining Alaunos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 97 Alaunos Therapeutics shares in Q3 2023, an estimated $7.43K.
  • Raymond James Financial Services Advisors first reported a position in Alaunos Therapeutics in Q3 2015 and held it in 30 quarters.
  • Raymond James Financial Services Advisors's Alaunos Therapeutics position peaked at $1.54M in Q4 2015.
  • 89 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.